Related Experiment Video
Updated: May 4, 2026
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Second-generation prophylactic HPV vaccines: successes and challenges
Mitchell Tyler1, Ebenezer Tumban, Bryce Chackerian
1Department of Molecular Genetics and Microbiology, University of New Mexico, Albuquerque, NM 87131, USA.
Abstract:
The role of HPV as the causative factor in cervical cancer has led to the development of the HPV vaccines Gardasil and Cervarix. These vaccines effectively protect against two HPV types associated with 70% of cervical cancer cases. Despite this success, researchers continue to develop second-generation HPV vaccines to protect against more HPV types and allow increased uptake in developing countries. While a reformulated vaccine based on the current technology is currently in clinical trials, another strategy consists of targeting highly conserved epitopes in the minor capsid protein of HPV, L2. Vaccines targeting L2 induce broadly neutralizing antibodies, capable of blocking infection by a wide range of HPV types. Several vaccine designs have been developed to optimize the display of L2 epitopes to the immune system and to reduce the cost of manufacture and distribution. L2-based vaccines show considerable promise as a potential next-generation HPV vaccine.
Insights
Human papillomavirus (HPV) vaccines like Gardasil and Cervarix target key types. New L2-based vaccines aim for broader protection against diverse HPV types, enhancing cervical cancer prevention globally.
Area of Science:
- Oncology
- Immunology
- Vaccinology
Background:
- Human papillomavirus (HPV) is the primary cause of cervical cancer.
- Current HPV vaccines (Gardasil, Cervarix) target specific HPV types, covering ~70% of cases.
- Development of next-generation vaccines is crucial for broader protection and global health equity.
Purpose of the Study:
- To explore the potential of second-generation HPV vaccines.
- To investigate L2-based vaccine strategies for broader HPV type coverage.
- To assess novel vaccine designs for improved manufacturing and distribution.
Main Methods:
- Review of current HPV vaccine technology and limitations.
- Analysis of L2 minor capsid protein as a target for broadly neutralizing antibodies.
- Examination of various L2-based vaccine designs optimizing epitope display and cost-effectiveness.
Main Results:
- L2-based vaccines induce broadly neutralizing antibodies against multiple HPV types.
- Optimized vaccine designs enhance L2 epitope presentation to the immune system.
- L2 strategies offer potential for reduced manufacturing and distribution costs.
Conclusions:
- L2-based vaccines represent a promising next-generation approach to HPV prevention.
- These vaccines have the potential to overcome limitations of current HPV vaccines.
- Further development of L2 vaccines could significantly impact global cervical cancer rates.
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:51Vaccinations
01:21Vaccines
01:29Microorganisms in Medicine and Therapeutics
01:22Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...